​

Trevi Therapeutics Ownership | Who Owns Trevi Therapeutics?

OverviewForecastFinancialsChartTranscripts

Trevi Therapeutics Ownership Summary

Trevi Therapeutics is owned by 44.72% institutional investors, 0.68% insiders, and 54.59% retail investors. Nea management company is the largest institutional shareholder, holding 10.14% of TRVI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.67% of its assets in Trevi Therapeutics shares.

TRVI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTrevi Therapeutics44.72%0.68%54.59%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company13.22M10.14%$120.98M
Frazier life sciences management10.26M7.87%$93.87M
Blackrock funding, inc. /de10.13M6.98%$126.78M
Vanguard group6.43M4.43%$80.56M
Viking global investors lp5.13M3.93%$46.93M
Vivo capital5.09M3.91%$46.62M
Marshall wace, llp4.84M3.71%$44.30M
Alliancebernstein4.29M3.29%$39.28M
Blackrock3.14M3.15%$9.34M
Bioimpact capital3.41M2.61%$31.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acorn capital advisors2.14M9.96%$19.63M
Pivotal bioventure partners investment advisor1.26M6.65%$11.50M
Nea management company13.22M6.64%$120.98M
Bioimpact capital3.41M5.10%$31.17M
Octagon capital advisors lp2.81M3.90%$25.76M
Vivo capital5.09M3.75%$46.62M
Artia global partners lp2.00M2.90%$18.30M
Frazier life sciences management10.26M2.81%$93.87M
Affinity asset advisors2.80M2.23%$25.62M
Logos global management lp2.20M1.80%$20.13M

Top Buyers

HolderShares% AssetsChange
Viking global investors lp5.13M0.12%3.59M
Wellington management group llp3.25M0.01%3.08M
Fmr3.30M0.00%2.93M
Marshall wace, llp4.84M0.04%2.36M
Emerald advisers1.89M0.73%1.89M

Top Sellers

HolderShares% AssetsChange
Rubric capital management lp3.77M0.56%-4.77M
Woodline partners lp100.28K0.00%-3.95M
Morgan stanley1.05M0.00%-3.25M
Armistice capital---2.99M
Siren2.54M0.91%-1.40M

New Positions

HolderShares% AssetsChangeValue
Emerald advisers1.89M0.73%1.89M$23.69M
Emerald mutual fund advisers trust1.27M0.78%1.27M$15.93M
Stempoint capital lp350.71K0.64%350.71K$3.21M
F/m investments241.48K0.11%241.48K$3.02M
Velan capital investment management lp205.00K1.76%205.00K$1.88M

Sold Out

HolderChange
Eversource wealth advisors-1.00
Twin peaks wealth advisors-2.00
Nelson, van denburg & campbell wealth management group-6.00
Clearstead advisors-39.00
Rothschild investment-40.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025113-34.30%64,895,069-49.82%440.45%68-32.67%27-37.21%
Sep 30, 20251699.03%127,167,79618.08%971.43%99-1.98%4334.38%
Jun 30, 202516214.08%114,632,70430.70%871.58%1046.12%336.45%
Mar 31, 202514224.56%88,122,13510.86%741.21%9836.11%3233.33%
Dec 31, 202410710.31%67,554,27516.23%662.02%6634.69%2531.58%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.42M2.67%-
Fidelity Select Biotechnology2.58M2.01%-120.10K
Vanguard US Total Market Shares ETF1.78M1.84%-
iShares Russell 2000 ETF2.20M1.71%2.20M
AB Small Cap Growth A1.40M1.09%-263.98K
Eventide Healthcare & Life Sciences I1.38M1.08%-
MEDICAL BioHealth EUR Acc1.33M1.03%544.85K
Vanguard Institutional Extnd Mkt Idx Tr1.12M0.88%-3.12K
Biotech Growth Ord1.03M0.80%15.80K
Fidelity Small Cap Index880.69K0.69%2.82K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 25, 2025SCIASCIA THOMAS Chief Scientific OfficerSell$17.36K
Mar 21, 2025GOOD JENNIFER L President & CEOSell$34.62K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$31.10K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$517.78K
Sep 06, 2024GOOD JENNIFER L President & CEOSell$12.78K

Insider Transactions Trends

DateBuySell
2026 Q1--
2025 Q4--
2025 Q2--
2025 Q1-4
2024 Q4--

TRVI Ownership FAQ

Who Owns Trevi Therapeutics?

Trevi Therapeutics shareholders are primarily institutional investors at 44.72%, followed by 0.68% insiders and 54.60% retail investors. The average institutional ownership in Trevi Therapeutics's industry, Biotech Stocks , is 381.47%, which Trevi Therapeutics falls below.

Who owns the most shares of Trevi Therapeutics?

Trevi Therapeutics’s largest shareholders are Nea management company (13.22M shares, 10.14%), Frazier life sciences management (10.26M shares, 7.87%), and Blackrock funding, inc. /de (10.13M shares, 6.98%). Together, they hold 24.99% of Trevi Therapeutics’s total shares outstanding.

Does Blackrock own Trevi Therapeutics?

Yes, BlackRock owns 3.15% of Trevi Therapeutics, totaling 3.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 9.34M$. In the last quarter, BlackRock increased its holdings by 759.41K shares, a 31.97% change.

Who is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested?

Acorn capital advisors is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.96% of its assets in 2.14M Trevi Therapeutics shares, valued at 19.63M$.

Who is the top mutual fund holder of Trevi Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Trevi Therapeutics shares, with 2.67% of its total shares outstanding invested in 3.42M Trevi Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools